Edgewise doses first patient in Phase 2 heart-failure trial of EDG-15400
What's the deal? Edgewise Therapeutics has dosed the first patient in EQUINOX-HFpEF, a Phase 2 clinical trial of EDG-15400, its investigational cardiac sarcomere modulator ( a medicine that tunes how heart muscle proteins generate force), in adults with symptomatic heart failure with preserved ejection fraction (HFpEF — heart failure where the heart's pumping chamber fills abnormally but still squeezes normally.). Participants will take once-daily oral doses of EDG-15400 ( 25 mg or ️50 mg) or placebo for up to 12 weeks, with the study aiming to enrol about ️90 patients. The announcement came on ️8 October 2026.
Why it matters: HFpEF is common, hard to diagnose and treat, and accounts for around half of all heart-failure cases, with few medicines shown to improve outcomes. Patients typically suffer breathlessness, fatigue and fluid build-up that limit daily life. EDG-15400 takes a different approach: instead of relaxing or strengthening blood vessels, it acts directly on the heart muscle's sarcomere machinery to make the heartbeat more efficient. Success would give Edgewise, which built its name on rare muscle-disease programmes, a potential new mechanism for one of cardiology's biggest unmet needs.
Read more: PR Newswire, 8 October 2026